Previous 10 | Next 10 |
HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...
Arcutis Biotherapeutics Inc. (ARQT) is expected to report $-0.9 for Q3 2023
2023-10-26 19:20:36 ET More on Arcutis Biotherapeutics Arcutis Biotherapeutics, Inc. (ARQT) Q2 2023 Earnings Call Transcript Arcutis Biotherapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation Arcutis announces pricing of $100 million public offering ...
2023-10-26 08:35:12 ET More on Golden Minerals, Opendoor Technologies, etc. Opendoor Technologies Inc. (OPEN) Goldman Sachs 2023 Communacopia & Technology Conference Transcript Opendoor: The Bottom May Be Here For The Brave Rentokil Initial: Thriving Compounder I...
WESTLAKE VILLAGE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 8:30 a.m. ET o...
2023-10-20 10:06:59 ET More on Health Care: Health Care Select Sector Fund ETF: Riding The Healthcare Boom September Labor Report Preview: Full Employment To Infinity Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the...
2023-10-20 08:43:02 ET Losers: WeBuy Global Ltd ( WBUY ) -33% . Solaredge Technologies ( SEDG ) -30% posts big miss on preliminary Q3 sales . Alpine 4 Holdings ( ALPP ) -19% . Arcutis Biotherapeutics ( ARQT ) -19% announces pricing of ...
Individual patient response data highlights 95% of individuals treated with ZORYVE had a measurable improvement in Psoriasis Area and Severity Index (PASI) at Week 8 Over 85% achieved measurable improvement by Week 2 (the earliest timepoint measured) Separately reported new data confirms ...
2023-10-20 06:10:30 ET Arcutis Biotherapeutics ( NASDAQ: ARQT ) is selling 32,500,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 7,500,000 shares of common stock in the offering. The shares of common stock are bein...
WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritt...
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
Arcutis Biotherapeutics Inc. Website:
ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of atopic dermatitis (AD) Once-daily cream is for use anywhere on the body for any duration...
WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Company has been in communication with the U....
2024-06-16 18:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...